Abingworth LLP Buys Aeglea BioTherapeutics Inc, Realm Therapeutics PLC, Histogenics Corp, Sells ObsEva SA, Aurinia Pharmaceuticals Inc, Cellectis SA

• New Purchases: AGLE, RLM,
• Added Positions: SIEN, HSGX,
• Reduced Positions: OBSV, SRRA,
• Sold Out: AUPH, CLLS, RARE, ADAP, IMDZ,

For the details of Abingworth LLP's stock buys and sells, go to https://www.gurufocus.com/guru/abingworth+llp/current-portfolio/portfolio

1. CRISPR Therapeutics AG (CRSP) - 1,171,268 shares, 40.61% of the total portfolio.
2. Sientra Inc (SIEN) - 2,390,843 shares, 19.87% of the total portfolio. Shares added by 8.72%
3. Chiasma Inc (CHMA) - 2,080,595 shares, 10.38% of the total portfolio.
4. Soleno Therapeutics Inc (SLNO) - 4,669,272 shares, 9.34% of the total portfolio.
5. Paratek Pharmaceuticals Inc (PRTK) - 1,041,131 shares, 5.43% of the total portfolio.

Abingworth LLP initiated holding in Aeglea BioTherapeutics Inc. The purchase prices were between $7.49 and $9.4, with an estimated average price of $8.33. The stock is now traded at around $6.81. The impact to a portfolio due to this purchase was 1.88%. The holding were 240,500 shares as of .

Abingworth LLP initiated holding in Realm Therapeutics PLC. The purchase prices were between $1.81 and $4.25, with an estimated average price of $2.76. The stock is now traded at around $3.31. The impact to a portfolio due to this purchase was 0.96%. The holding were 255,371 shares as of .

Abingworth LLP added to a holding in Histogenics Corp by 100.00%. The purchase prices were between $0.09 and $0.22, with an estimated average price of $0.14. The stock is now traded at around $0.19. The impact to a portfolio due to this purchase was 0.1%. The holding were 1,777,778 shares as of .

Abingworth LLP sold out a holding in Aurinia Pharmaceuticals Inc. The sale prices were between $6.06 and $7.64, with an estimated average price of $6.65.

Abingworth LLP sold out a holding in Cellectis SA. The sale prices were between $15.53 and $19.75, with an estimated average price of $17.69.

Abingworth LLP sold out a holding in Ultragenyx Pharmaceutical Inc. The sale prices were between $39.87 and $69.36, with an estimated average price of $56.86.

Abingworth LLP sold out a holding in Adaptimmune Therapeutics PLC. The sale prices were between $3.63 and $6.06, with an estimated average price of $4.68.

Abingworth LLP sold out a holding in Immune Design Corp. The sale prices were between $1.3 and $5.85, with an estimated average price of $3.31.